Brian Freed
Concepts (510)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
HLA-DRB1 Chains | 7 | 2016 | 98 | 1.760 |
Why?
| T-Lymphocytes | 21 | 2018 | 1814 | 1.630 |
Why?
| Epitopes | 4 | 2016 | 450 | 1.370 |
Why?
| HLA Antigens | 8 | 2019 | 230 | 0.980 |
Why?
| Genetic Predisposition to Disease | 6 | 2016 | 2359 | 0.980 |
Why?
| Lymphocyte Activation | 19 | 2006 | 1148 | 0.950 |
Why?
| Interleukin-2 | 16 | 2005 | 420 | 0.870 |
Why?
| Arthritis, Rheumatoid | 3 | 2016 | 985 | 0.860 |
Why?
| Lymphoma, Non-Hodgkin | 1 | 2022 | 73 | 0.830 |
Why?
| Hydroquinones | 6 | 2003 | 25 | 0.790 |
Why?
| Kidney Transplantation | 20 | 2019 | 584 | 0.780 |
Why?
| HLA-DR Antigens | 5 | 2020 | 228 | 0.670 |
Why?
| Tars | 3 | 2006 | 4 | 0.640 |
Why?
| Graft Rejection | 14 | 2019 | 556 | 0.630 |
Why?
| Alleles | 7 | 2019 | 852 | 0.600 |
Why?
| Immunosuppressive Agents | 13 | 2017 | 687 | 0.580 |
Why?
| Acrolein | 2 | 2007 | 25 | 0.570 |
Why?
| Vimentin | 2 | 2016 | 62 | 0.550 |
Why?
| Cyclosporins | 11 | 1991 | 60 | 0.550 |
Why?
| HLA-B Antigens | 2 | 2022 | 55 | 0.490 |
Why?
| Catechols | 4 | 2003 | 16 | 0.490 |
Why?
| Peptides, Cyclic | 2 | 2016 | 260 | 0.480 |
Why?
| Peptides | 2 | 2016 | 893 | 0.470 |
Why?
| Tissue Donors | 6 | 2018 | 337 | 0.470 |
Why?
| Histocompatibility Antigens Class I | 3 | 2022 | 176 | 0.470 |
Why?
| Fetal Blood | 6 | 2024 | 275 | 0.430 |
Why?
| Programmed Cell Death 1 Receptor | 3 | 2020 | 201 | 0.430 |
Why?
| Histocompatibility Antigens Class II | 5 | 2022 | 397 | 0.430 |
Why?
| Cord Blood Stem Cell Transplantation | 5 | 2016 | 96 | 0.410 |
Why?
| Smoking | 5 | 2011 | 1556 | 0.400 |
Why?
| DNA | 7 | 2007 | 1401 | 0.400 |
Why?
| Smoke | 5 | 2007 | 146 | 0.400 |
Why?
| B-Lymphocytes | 7 | 2021 | 936 | 0.390 |
Why?
| Enzyme-Linked Immunosorbent Assay | 5 | 2013 | 839 | 0.380 |
Why?
| Humans | 90 | 2024 | 122796 | 0.360 |
Why?
| Ribonucleotide Reductases | 2 | 2000 | 30 | 0.350 |
Why?
| Graft Survival | 9 | 2017 | 500 | 0.350 |
Why?
| Immunoglobulin G | 4 | 2013 | 804 | 0.340 |
Why?
| Immunoglobulin E | 1 | 2010 | 368 | 0.330 |
Why?
| Arachis | 1 | 2010 | 151 | 0.330 |
Why?
| Lymphocytes | 3 | 2013 | 360 | 0.310 |
Why?
| Disease Models, Animal | 5 | 2021 | 3799 | 0.310 |
Why?
| NF-kappa B p50 Subunit | 1 | 2007 | 26 | 0.300 |
Why?
| Cells, Cultured | 11 | 2019 | 4162 | 0.300 |
Why?
| Isoantibodies | 3 | 2017 | 64 | 0.300 |
Why?
| Peanut Hypersensitivity | 1 | 2010 | 204 | 0.290 |
Why?
| CD4-Positive T-Lymphocytes | 5 | 2016 | 1003 | 0.280 |
Why?
| Plants, Toxic | 3 | 2000 | 28 | 0.280 |
Why?
| Cyclin-Dependent Kinase 4 | 1 | 2006 | 32 | 0.280 |
Why?
| Cyclin-Dependent Kinase 6 | 1 | 2006 | 37 | 0.280 |
Why?
| Flow Cytometry | 5 | 2016 | 1128 | 0.270 |
Why?
| Histocompatibility Testing | 7 | 2019 | 123 | 0.270 |
Why?
| Immune System | 2 | 2021 | 184 | 0.270 |
Why?
| Tuberculosis | 2 | 2023 | 266 | 0.270 |
Why?
| Hematopoietic Stem Cell Transplantation | 3 | 2024 | 543 | 0.260 |
Why?
| Mycobacterium tuberculosis | 2 | 2023 | 304 | 0.260 |
Why?
| Ethylmaleimide | 3 | 1991 | 18 | 0.260 |
Why?
| Enzyme Inhibitors | 2 | 2000 | 836 | 0.250 |
Why?
| Antibodies | 3 | 2019 | 400 | 0.250 |
Why?
| Haplotypes | 3 | 2014 | 482 | 0.250 |
Why?
| Ganciclovir | 4 | 1997 | 46 | 0.250 |
Why?
| Cell Line | 10 | 2016 | 2785 | 0.240 |
Why?
| Cytomegalovirus Infections | 5 | 1997 | 188 | 0.230 |
Why?
| Diabetes Mellitus, Type 1 | 5 | 2014 | 3388 | 0.230 |
Why?
| Gene Frequency | 3 | 2019 | 522 | 0.230 |
Why?
| Islets of Langerhans | 3 | 1994 | 749 | 0.220 |
Why?
| Transplantation, Haploidentical | 1 | 2022 | 7 | 0.220 |
Why?
| HLA-A Antigens | 1 | 2022 | 52 | 0.220 |
Why?
| HLA-C Antigens | 1 | 2022 | 33 | 0.220 |
Why?
| Cyclosporine | 5 | 1998 | 175 | 0.210 |
Why?
| Cigarette Smoking | 1 | 2023 | 87 | 0.210 |
Why?
| Protein Binding | 3 | 2016 | 2010 | 0.210 |
Why?
| Interferon-gamma | 3 | 2005 | 747 | 0.210 |
Why?
| Histocompatibility Antigens | 1 | 2022 | 105 | 0.210 |
Why?
| Tumor Necrosis Factor-alpha | 3 | 2005 | 1181 | 0.210 |
Why?
| Enoxaparin | 1 | 2022 | 52 | 0.210 |
Why?
| Receptors, KIR | 2 | 2022 | 89 | 0.200 |
Why?
| Central Tolerance | 1 | 2021 | 8 | 0.200 |
Why?
| In Vitro Techniques | 9 | 2005 | 1130 | 0.200 |
Why?
| Precursor Cells, B-Lymphoid | 1 | 2021 | 35 | 0.200 |
Why?
| DNA-Binding Proteins | 2 | 2011 | 1384 | 0.200 |
Why?
| Receptors, CXCR4 | 1 | 2021 | 85 | 0.190 |
Why?
| Immune Tolerance | 3 | 2021 | 355 | 0.190 |
Why?
| HLA-DRB4 Chains | 1 | 2020 | 6 | 0.190 |
Why?
| Transplantation, Homologous | 9 | 2019 | 413 | 0.190 |
Why?
| Heterografts | 1 | 2021 | 132 | 0.190 |
Why?
| Receptors, Interleukin-2 | 5 | 2003 | 73 | 0.190 |
Why?
| Brain Ischemia | 1 | 2024 | 311 | 0.180 |
Why?
| Antineoplastic Agents, Immunological | 2 | 2020 | 159 | 0.180 |
Why?
| Nickel | 1 | 2020 | 52 | 0.180 |
Why?
| Gene Expression Regulation | 3 | 2016 | 2491 | 0.180 |
Why?
| Trace Elements | 1 | 2020 | 50 | 0.180 |
Why?
| Cell Division | 4 | 1997 | 788 | 0.180 |
Why?
| Immunotherapy | 2 | 2021 | 504 | 0.180 |
Why?
| Tumor Microenvironment | 2 | 2020 | 457 | 0.180 |
Why?
| Mice | 17 | 2023 | 15888 | 0.180 |
Why?
| Transcription Factors | 2 | 2005 | 1616 | 0.180 |
Why?
| alpha 1-Antitrypsin | 1 | 2020 | 123 | 0.180 |
Why?
| Adrenal Cortex Neoplasms | 1 | 2020 | 49 | 0.170 |
Why?
| Insulin | 3 | 1994 | 2180 | 0.170 |
Why?
| Adrenocortical Carcinoma | 1 | 2020 | 48 | 0.170 |
Why?
| Pulmonary Alveolar Proteinosis | 1 | 2019 | 17 | 0.170 |
Why?
| Cell Cycle Proteins | 1 | 2003 | 576 | 0.170 |
Why?
| Receptors, Antigen, B-Cell | 2 | 2021 | 215 | 0.170 |
Why?
| Vascular System Injuries | 1 | 2019 | 72 | 0.170 |
Why?
| Tacrolimus | 2 | 2017 | 154 | 0.170 |
Why?
| Unrelated Donors | 2 | 2024 | 38 | 0.170 |
Why?
| HEK293 Cells | 2 | 2022 | 651 | 0.160 |
Why?
| Transcription, Genetic | 2 | 2003 | 1355 | 0.160 |
Why?
| Peripheral Blood Stem Cell Transplantation | 1 | 2018 | 19 | 0.160 |
Why?
| Animals | 25 | 2023 | 34133 | 0.160 |
Why?
| Herpesvirus 4, Human | 1 | 2018 | 127 | 0.160 |
Why?
| Epstein-Barr Virus Infections | 1 | 2018 | 73 | 0.160 |
Why?
| Hydrogen Peroxide | 3 | 1988 | 299 | 0.150 |
Why?
| Cell Transplantation | 1 | 1997 | 39 | 0.150 |
Why?
| Antiviral Agents | 3 | 2020 | 670 | 0.150 |
Why?
| Lymphoma, Large B-Cell, Diffuse | 1 | 2018 | 93 | 0.150 |
Why?
| Donor Selection | 1 | 2018 | 73 | 0.150 |
Why?
| Histone Deacetylase Inhibitors | 1 | 2019 | 202 | 0.150 |
Why?
| Proinsulin | 1 | 1997 | 49 | 0.150 |
Why?
| Carcinogenesis | 1 | 2018 | 184 | 0.150 |
Why?
| Hypersensitivity | 1 | 2020 | 259 | 0.150 |
Why?
| Mutagenesis, Site-Directed | 2 | 2016 | 368 | 0.150 |
Why?
| Transplantation Conditioning | 1 | 2018 | 158 | 0.150 |
Why?
| Benzoquinones | 1 | 1997 | 45 | 0.150 |
Why?
| Complement System Proteins | 1 | 2019 | 296 | 0.150 |
Why?
| Neoplasm Recurrence, Local | 1 | 2022 | 903 | 0.150 |
Why?
| Mice, Inbred BALB C | 5 | 2021 | 1245 | 0.140 |
Why?
| Amino Acid Sequence | 4 | 2016 | 2123 | 0.140 |
Why?
| Triple Negative Breast Neoplasms | 1 | 2019 | 164 | 0.140 |
Why?
| Phosphopyruvate Hydratase | 1 | 2016 | 35 | 0.140 |
Why?
| Female | 28 | 2021 | 63629 | 0.140 |
Why?
| Dextrans | 1 | 2016 | 77 | 0.140 |
Why?
| Genetic Variation | 2 | 2015 | 952 | 0.140 |
Why?
| HLA-DQ beta-Chains | 1 | 2016 | 62 | 0.140 |
Why?
| Collagen Type II | 1 | 2016 | 48 | 0.140 |
Why?
| Cytotoxicity, Immunologic | 3 | 2012 | 204 | 0.140 |
Why?
| Autoantibodies | 4 | 2021 | 1353 | 0.140 |
Why?
| Interleukin-1 | 1 | 2000 | 987 | 0.140 |
Why?
| Adult | 18 | 2019 | 32385 | 0.130 |
Why?
| Sequence Homology, Amino Acid | 1 | 2016 | 376 | 0.130 |
Why?
| Genetic Therapy | 1 | 1997 | 265 | 0.130 |
Why?
| Autoimmune Diseases | 1 | 2019 | 408 | 0.130 |
Why?
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 658 | 0.130 |
Why?
| Resting Phase, Cell Cycle | 2 | 2006 | 15 | 0.130 |
Why?
| Genotype | 3 | 2022 | 1943 | 0.130 |
Why?
| Kidney Failure, Chronic | 2 | 2017 | 519 | 0.130 |
Why?
| Stroke | 1 | 2024 | 1090 | 0.130 |
Why?
| Methylprednisolone | 3 | 1991 | 86 | 0.130 |
Why?
| G1 Phase | 2 | 2006 | 71 | 0.130 |
Why?
| Protein Kinase C | 1 | 1996 | 314 | 0.120 |
Why?
| Tobacco Smoke Pollution | 1 | 1997 | 235 | 0.120 |
Why?
| Clonal Anergy | 1 | 1994 | 75 | 0.120 |
Why?
| Endothelial Cells | 1 | 2019 | 749 | 0.120 |
Why?
| Retrospective Studies | 9 | 2022 | 13433 | 0.120 |
Why?
| Immunoglobulin Isotypes | 1 | 2013 | 32 | 0.120 |
Why?
| Autoimmunity | 2 | 2021 | 852 | 0.120 |
Why?
| Lymphocyte Culture Test, Mixed | 7 | 1996 | 47 | 0.120 |
Why?
| Indoles | 1 | 1996 | 318 | 0.120 |
Why?
| Tumor Cells, Cultured | 4 | 2020 | 904 | 0.120 |
Why?
| Sequence Analysis, RNA | 1 | 2016 | 420 | 0.120 |
Why?
| Dried Blood Spot Testing | 1 | 2013 | 70 | 0.120 |
Why?
| C-Reactive Protein | 2 | 1987 | 363 | 0.120 |
Why?
| Cell Cycle | 3 | 2006 | 584 | 0.120 |
Why?
| Pulmonary Fibrosis | 1 | 2016 | 305 | 0.120 |
Why?
| Hypoxanthine Phosphoribosyltransferase | 1 | 2013 | 26 | 0.110 |
Why?
| Xenograft Model Antitumor Assays | 3 | 2021 | 747 | 0.110 |
Why?
| Radioimmunoassay | 5 | 1990 | 168 | 0.110 |
Why?
| Male | 22 | 2021 | 59639 | 0.110 |
Why?
| Models, Biological | 1 | 2020 | 1756 | 0.110 |
Why?
| Models, Animal | 2 | 2013 | 373 | 0.110 |
Why?
| Transduction, Genetic | 1 | 2013 | 118 | 0.110 |
Why?
| Complementarity Determining Regions | 1 | 2012 | 45 | 0.110 |
Why?
| Postoperative Complications | 5 | 2017 | 2301 | 0.110 |
Why?
| Islets of Langerhans Transplantation | 1 | 1992 | 68 | 0.110 |
Why?
| Leukemia L1210 | 1 | 1992 | 7 | 0.110 |
Why?
| Receptors, Antigen, T-Cell, alpha-beta | 2 | 2012 | 314 | 0.110 |
Why?
| Chagas Disease | 1 | 2012 | 35 | 0.100 |
Why?
| Child, Preschool | 6 | 2014 | 9755 | 0.100 |
Why?
| Colorectal Neoplasms | 1 | 2019 | 646 | 0.100 |
Why?
| Gene Knockdown Techniques | 1 | 2013 | 322 | 0.100 |
Why?
| Middle Aged | 12 | 2019 | 28563 | 0.100 |
Why?
| Lung | 4 | 2007 | 3830 | 0.100 |
Why?
| Beryllium | 2 | 2005 | 152 | 0.100 |
Why?
| Blood Specimen Collection | 1 | 2011 | 35 | 0.100 |
Why?
| Fibroblasts | 2 | 1994 | 846 | 0.100 |
Why?
| Bronchiolitis Obliterans | 1 | 2012 | 69 | 0.100 |
Why?
| Mice, Knockout | 5 | 2021 | 2737 | 0.100 |
Why?
| Blood Banks | 1 | 2011 | 43 | 0.100 |
Why?
| Interleukin Receptor Common gamma Subunit | 1 | 2011 | 15 | 0.100 |
Why?
| Chromatography, High Pressure Liquid | 7 | 2005 | 493 | 0.100 |
Why?
| Transplantation Chimera | 1 | 2011 | 51 | 0.100 |
Why?
| Maleimides | 1 | 1991 | 24 | 0.100 |
Why?
| International Cooperation | 1 | 2011 | 182 | 0.100 |
Why?
| Serine Endopeptidases | 2 | 2022 | 104 | 0.100 |
Why?
| Receptors, Transferrin | 2 | 2003 | 24 | 0.100 |
Why?
| Calcium | 2 | 1994 | 1244 | 0.100 |
Why?
| Spleen | 1 | 2013 | 543 | 0.100 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 1402 | 0.100 |
Why?
| Idiopathic Pulmonary Fibrosis | 1 | 2016 | 456 | 0.090 |
Why?
| Mitogens | 2 | 1988 | 61 | 0.090 |
Why?
| Skin Tests | 1 | 2010 | 134 | 0.090 |
Why?
| Algorithms | 1 | 2018 | 1593 | 0.090 |
Why?
| Lymph Nodes | 1 | 2013 | 466 | 0.090 |
Why?
| Hematopoietic Stem Cells | 1 | 2013 | 370 | 0.090 |
Why?
| Antibody Formation | 1 | 1991 | 285 | 0.090 |
Why?
| Nicotine | 2 | 2023 | 276 | 0.090 |
Why?
| Jurkat Cells | 2 | 2000 | 139 | 0.090 |
Why?
| Cesarean Section | 1 | 2011 | 184 | 0.090 |
Why?
| Siblings | 1 | 2010 | 235 | 0.090 |
Why?
| Genes, T-Cell Receptor beta | 2 | 2007 | 20 | 0.090 |
Why?
| Survival Rate | 5 | 2017 | 1810 | 0.090 |
Why?
| Lung Transplantation | 1 | 2012 | 273 | 0.090 |
Why?
| Genome-Wide Association Study | 1 | 2016 | 1376 | 0.090 |
Why?
| Cricetinae | 3 | 1994 | 269 | 0.090 |
Why?
| HLA-DQ Antigens | 2 | 2000 | 178 | 0.090 |
Why?
| Base Sequence | 3 | 2012 | 2186 | 0.080 |
Why?
| Immunoglobulins, Intravenous | 3 | 1995 | 130 | 0.080 |
Why?
| Adolescent | 7 | 2014 | 18948 | 0.080 |
Why?
| Disease Susceptibility | 1 | 2011 | 343 | 0.080 |
Why?
| Lymphocytes, Tumor-Infiltrating | 2 | 2020 | 115 | 0.080 |
Why?
| Anemia, Sickle Cell | 1 | 2012 | 226 | 0.080 |
Why?
| Cell Survival | 3 | 1997 | 1075 | 0.080 |
Why?
| CD8-Positive T-Lymphocytes | 2 | 2019 | 715 | 0.080 |
Why?
| Phytohemagglutinins | 4 | 1991 | 27 | 0.080 |
Why?
| Allografts | 2 | 2019 | 132 | 0.080 |
Why?
| Amino Acids | 1 | 2011 | 463 | 0.080 |
Why?
| Mice, Nude | 2 | 2020 | 668 | 0.080 |
Why?
| Cell Differentiation | 4 | 2021 | 1805 | 0.080 |
Why?
| Mice, Inbred NOD | 2 | 2021 | 588 | 0.080 |
Why?
| Genetic Linkage | 2 | 2006 | 328 | 0.080 |
Why?
| Isoantigens | 1 | 1987 | 20 | 0.080 |
Why?
| Molecular Sequence Data | 3 | 2012 | 2933 | 0.070 |
Why?
| Transcription Factor AP-1 | 1 | 2007 | 82 | 0.070 |
Why?
| NFATC Transcription Factors | 1 | 2007 | 83 | 0.070 |
Why?
| Neoplasms | 1 | 2021 | 2235 | 0.070 |
Why?
| Follow-Up Studies | 5 | 2018 | 4768 | 0.070 |
Why?
| Cloning, Molecular | 2 | 1998 | 551 | 0.070 |
Why?
| Kidney Function Tests | 2 | 2017 | 166 | 0.070 |
Why?
| Prognosis | 4 | 2017 | 3563 | 0.070 |
Why?
| HLA-B15 Antigen | 1 | 2006 | 12 | 0.070 |
Why?
| Aldehydes | 1 | 2007 | 155 | 0.070 |
Why?
| Muromonab-CD3 | 2 | 1997 | 23 | 0.070 |
Why?
| Enzyme Induction | 1 | 2006 | 94 | 0.070 |
Why?
| Sequence Homology | 1 | 2006 | 40 | 0.070 |
Why?
| Butylated Hydroxytoluene | 1 | 2006 | 31 | 0.070 |
Why?
| Bone Marrow | 2 | 2021 | 257 | 0.070 |
Why?
| Cysteine | 1 | 2007 | 187 | 0.070 |
Why?
| Lung Diseases | 2 | 2006 | 764 | 0.070 |
Why?
| Arginine | 1 | 2007 | 254 | 0.070 |
Why?
| Microspheres | 1 | 2006 | 132 | 0.070 |
Why?
| HLA-DP Antigens | 1 | 2005 | 33 | 0.070 |
Why?
| Phenotype | 3 | 2021 | 3070 | 0.070 |
Why?
| Autoantigens | 2 | 2021 | 407 | 0.070 |
Why?
| Child | 5 | 2014 | 19561 | 0.070 |
Why?
| Phospholipases A | 1 | 2006 | 102 | 0.070 |
Why?
| Cell Proliferation | 2 | 2020 | 2328 | 0.070 |
Why?
| Phenols | 1 | 2006 | 87 | 0.070 |
Why?
| Transfection | 2 | 1998 | 909 | 0.070 |
Why?
| Gas Chromatography-Mass Spectrometry | 1 | 2005 | 139 | 0.070 |
Why?
| NAD(P)H Dehydrogenase (Quinone) | 1 | 2004 | 33 | 0.060 |
Why?
| Arteriosclerosis | 1 | 2005 | 90 | 0.060 |
Why?
| Chemokines, CXC | 1 | 2004 | 66 | 0.060 |
Why?
| Aged | 5 | 2018 | 20495 | 0.060 |
Why?
| Antigen Presentation | 1 | 2005 | 198 | 0.060 |
Why?
| Reoperation | 3 | 1998 | 570 | 0.060 |
Why?
| Acetylcysteine | 1 | 2005 | 150 | 0.060 |
Why?
| Biliary Atresia | 1 | 2007 | 226 | 0.060 |
Why?
| Surveys and Questionnaires | 1 | 2016 | 4882 | 0.060 |
Why?
| Structure-Activity Relationship | 3 | 1991 | 536 | 0.060 |
Why?
| Case-Control Studies | 1 | 2011 | 3296 | 0.060 |
Why?
| Agglutination | 2 | 1997 | 5 | 0.060 |
Why?
| Pandemics | 2 | 2024 | 1401 | 0.060 |
Why?
| Berylliosis | 1 | 2005 | 183 | 0.060 |
Why?
| Antigens, Differentiation, T-Lymphocyte | 1 | 2003 | 87 | 0.060 |
Why?
| Antigens, Differentiation, B-Lymphocyte | 1 | 2003 | 37 | 0.060 |
Why?
| Concanavalin A | 3 | 1988 | 76 | 0.060 |
Why?
| E2F Transcription Factors | 1 | 2003 | 56 | 0.060 |
Why?
| Lectins, C-Type | 1 | 2003 | 68 | 0.060 |
Why?
| Risk Factors | 6 | 2017 | 9381 | 0.060 |
Why?
| Glomerular Filtration Rate | 2 | 2017 | 697 | 0.060 |
Why?
| Immunophenotyping | 2 | 2015 | 288 | 0.060 |
Why?
| Mice, Transgenic | 2 | 2021 | 2079 | 0.060 |
Why?
| Biomarkers | 2 | 2019 | 3662 | 0.060 |
Why?
| Mesocricetus | 2 | 1992 | 33 | 0.060 |
Why?
| Respiratory Tract Infections | 1 | 2007 | 335 | 0.060 |
Why?
| Intercellular Signaling Peptides and Proteins | 1 | 2004 | 373 | 0.060 |
Why?
| Cell Line, Transformed | 2 | 1992 | 140 | 0.050 |
Why?
| Superoxide Dismutase | 1 | 2004 | 345 | 0.050 |
Why?
| Phosphoproteins | 1 | 2005 | 332 | 0.050 |
Why?
| Polymorphism, Genetic | 1 | 2006 | 666 | 0.050 |
Why?
| Proto-Oncogene Proteins c-myc | 1 | 2003 | 122 | 0.050 |
Why?
| Severity of Illness Index | 1 | 2010 | 2784 | 0.050 |
Why?
| Reactive Oxygen Species | 1 | 2005 | 592 | 0.050 |
Why?
| Cell Communication | 2 | 2013 | 287 | 0.050 |
Why?
| Cyclophosphamide | 1 | 2022 | 223 | 0.050 |
Why?
| T-Lymphocytes, Cytotoxic | 3 | 1987 | 160 | 0.050 |
Why?
| Drug Synergism | 2 | 1996 | 346 | 0.050 |
Why?
| Neutrophils | 2 | 2005 | 1246 | 0.050 |
Why?
| T-Lymphocyte Subsets | 2 | 2016 | 409 | 0.050 |
Why?
| Leukemia | 2 | 2012 | 209 | 0.050 |
Why?
| Chimerism | 1 | 2021 | 28 | 0.050 |
Why?
| Iron Chelating Agents | 1 | 2000 | 16 | 0.050 |
Why?
| Kidney | 4 | 2019 | 1355 | 0.050 |
Why?
| Lymphocyte Subsets | 1 | 2021 | 78 | 0.050 |
Why?
| Lymphoid Tissue | 1 | 2021 | 66 | 0.050 |
Why?
| Cell Separation | 2 | 2011 | 303 | 0.050 |
Why?
| Antioxidants | 2 | 2006 | 581 | 0.050 |
Why?
| Virus Internalization | 1 | 2020 | 42 | 0.050 |
Why?
| RNA | 2 | 1997 | 854 | 0.050 |
Why?
| Antibody Specificity | 1 | 2001 | 190 | 0.050 |
Why?
| Ganglionic Stimulants | 1 | 2000 | 10 | 0.050 |
Why?
| Biopsy | 2 | 2019 | 1090 | 0.050 |
Why?
| Free Radicals | 1 | 2000 | 100 | 0.050 |
Why?
| T-Lymphocytes, Regulatory | 1 | 2023 | 367 | 0.050 |
Why?
| Apoptosis | 2 | 2020 | 2532 | 0.050 |
Why?
| Extracellular Traps | 1 | 2020 | 40 | 0.050 |
Why?
| Leukocyte Elastase | 1 | 2020 | 84 | 0.050 |
Why?
| Dimerization | 1 | 2000 | 184 | 0.050 |
Why?
| Antithrombins | 1 | 2020 | 57 | 0.050 |
Why?
| Antigens, CD | 1 | 2003 | 506 | 0.050 |
Why?
| Ligands | 1 | 2022 | 582 | 0.050 |
Why?
| Inflammation | 3 | 2006 | 2598 | 0.050 |
Why?
| Mice, SCID | 1 | 2021 | 339 | 0.050 |
Why?
| Nephelometry and Turbidimetry | 2 | 2013 | 15 | 0.050 |
Why?
| Bone Marrow Cells | 1 | 2021 | 282 | 0.050 |
Why?
| Blotting, Western | 2 | 2004 | 1225 | 0.050 |
Why?
| Arthroplasty, Replacement | 1 | 2020 | 49 | 0.050 |
Why?
| Gene Expression | 1 | 2005 | 1506 | 0.050 |
Why?
| Tyrosine | 1 | 2000 | 267 | 0.050 |
Why?
| Granuloma, Respiratory Tract | 1 | 1999 | 12 | 0.040 |
Why?
| Luminescent Measurements | 2 | 2013 | 72 | 0.040 |
Why?
| Treatment Outcome | 4 | 2024 | 9692 | 0.040 |
Why?
| Double-Blind Method | 1 | 2024 | 1711 | 0.040 |
Why?
| Young Adult | 2 | 2016 | 11094 | 0.040 |
Why?
| Receptors, Cytokine | 1 | 1999 | 34 | 0.040 |
Why?
| Xenobiotics | 1 | 1999 | 26 | 0.040 |
Why?
| Cytokines | 1 | 2007 | 1928 | 0.040 |
Why?
| Receptors, Interferon | 1 | 1999 | 50 | 0.040 |
Why?
| Steroid 21-Hydroxylase | 1 | 1999 | 29 | 0.040 |
Why?
| Antibodies, Monoclonal | 3 | 1991 | 1306 | 0.040 |
Why?
| Viral Tropism | 1 | 2018 | 24 | 0.040 |
Why?
| Addison Disease | 1 | 1999 | 40 | 0.040 |
Why?
| Metallothionein | 1 | 1998 | 24 | 0.040 |
Why?
| Antigens, CD34 | 2 | 2013 | 98 | 0.040 |
Why?
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2019 | 153 | 0.040 |
Why?
| Immunoglobulin M | 2 | 1991 | 288 | 0.040 |
Why?
| Virus Activation | 1 | 2018 | 80 | 0.040 |
Why?
| Virus Latency | 1 | 2018 | 80 | 0.040 |
Why?
| Mycophenolic Acid | 1 | 1998 | 80 | 0.040 |
Why?
| Leukocytes, Mononuclear | 2 | 2012 | 514 | 0.040 |
Why?
| Genotyping Techniques | 1 | 2018 | 77 | 0.040 |
Why?
| Pokeweed Mitogens | 2 | 1988 | 6 | 0.040 |
Why?
| Depression, Chemical | 1 | 1997 | 24 | 0.040 |
Why?
| RNA, Messenger | 1 | 2005 | 2720 | 0.040 |
Why?
| Drug Therapy, Combination | 2 | 1998 | 988 | 0.040 |
Why?
| Lymphocyte Function-Associated Antigen-1 | 1 | 1997 | 36 | 0.040 |
Why?
| 3T3 Cells | 1 | 1997 | 141 | 0.040 |
Why?
| Insulin, Long-Acting | 1 | 1997 | 49 | 0.040 |
Why?
| Acute Lung Injury | 1 | 2020 | 313 | 0.040 |
Why?
| Anti-Inflammatory Agents | 1 | 2020 | 469 | 0.040 |
Why?
| Complement Activation | 1 | 2019 | 349 | 0.040 |
Why?
| New York | 1 | 1997 | 121 | 0.040 |
Why?
| Guanidines | 1 | 1996 | 38 | 0.040 |
Why?
| Infant, Newborn | 2 | 2021 | 5430 | 0.040 |
Why?
| Sulfhydryl Compounds | 2 | 1991 | 190 | 0.040 |
Why?
| Contraindications | 1 | 2016 | 102 | 0.040 |
Why?
| S Phase | 1 | 1996 | 75 | 0.040 |
Why?
| Chromosomes, Human, Pair 6 | 1 | 2016 | 49 | 0.040 |
Why?
| Intercellular Adhesion Molecule-1 | 1 | 1997 | 177 | 0.040 |
Why?
| Immunoglobulin lambda-Chains | 1 | 2015 | 6 | 0.040 |
Why?
| Half-Life | 2 | 1996 | 147 | 0.030 |
Why?
| Immunoglobulin kappa-Chains | 1 | 2015 | 21 | 0.030 |
Why?
| Costs and Cost Analysis | 1 | 1997 | 211 | 0.030 |
Why?
| Liver | 3 | 2007 | 1827 | 0.030 |
Why?
| Iron | 1 | 1997 | 239 | 0.030 |
Why?
| Linkage Disequilibrium | 1 | 2016 | 279 | 0.030 |
Why?
| Antigens, CD19 | 1 | 2015 | 108 | 0.030 |
Why?
| Cross Reactions | 3 | 1990 | 118 | 0.030 |
Why?
| Antigens, Viral, Tumor | 1 | 1994 | 5 | 0.030 |
Why?
| B-Lymphocyte Subsets | 1 | 2015 | 81 | 0.030 |
Why?
| Desensitization, Immunologic | 1 | 2016 | 109 | 0.030 |
Why?
| Tetradecanoylphorbol Acetate | 1 | 1994 | 162 | 0.030 |
Why?
| Genetic Loci | 1 | 2016 | 296 | 0.030 |
Why?
| Transplant Recipients | 1 | 2016 | 149 | 0.030 |
Why?
| Prevalence | 1 | 2001 | 2442 | 0.030 |
Why?
| Mortality | 1 | 2016 | 317 | 0.030 |
Why?
| Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 2 | 2007 | 26 | 0.030 |
Why?
| Oxidative Stress | 1 | 2001 | 1204 | 0.030 |
Why?
| Mice, Inbred DBA | 2 | 1992 | 185 | 0.030 |
Why?
| Thioguanine | 1 | 2013 | 20 | 0.030 |
Why?
| Cell Adhesion | 1 | 1994 | 454 | 0.030 |
Why?
| Survivors | 1 | 2016 | 440 | 0.030 |
Why?
| Immunization, Passive | 1 | 1993 | 82 | 0.030 |
Why?
| Lymphocyte Count | 1 | 2013 | 141 | 0.030 |
Why?
| Umbilical Cord | 1 | 2013 | 82 | 0.030 |
Why?
| Mice, Inbred C57BL | 3 | 2011 | 5020 | 0.030 |
Why?
| Lymphocyte Depletion | 1 | 2013 | 127 | 0.030 |
Why?
| Drug Resistance | 1 | 2013 | 169 | 0.030 |
Why?
| Adoptive Transfer | 1 | 2013 | 214 | 0.030 |
Why?
| Myeloid Cells | 1 | 2013 | 129 | 0.030 |
Why?
| Anticoagulants | 1 | 2016 | 589 | 0.030 |
Why?
| Survival Analysis | 2 | 2012 | 1325 | 0.030 |
Why?
| Cell Line, Tumor | 1 | 2019 | 2904 | 0.030 |
Why?
| Mercaptopurine | 1 | 1991 | 15 | 0.030 |
Why?
| Seroepidemiologic Studies | 1 | 2012 | 147 | 0.030 |
Why?
| Lymphoma | 1 | 2012 | 185 | 0.020 |
Why?
| Polymorphism, Single Nucleotide | 1 | 2019 | 2127 | 0.020 |
Why?
| Signal Transduction | 2 | 2021 | 4902 | 0.020 |
Why?
| Bronchoalveolar Lavage Fluid | 2 | 2006 | 633 | 0.020 |
Why?
| Blood Donors | 1 | 2011 | 109 | 0.020 |
Why?
| Immunotherapy, Adoptive | 1 | 1992 | 192 | 0.020 |
Why?
| Preoperative Care | 1 | 2012 | 342 | 0.020 |
Why?
| Fetus | 1 | 2013 | 699 | 0.020 |
Why?
| Glucose | 1 | 1994 | 968 | 0.020 |
Why?
| Methylmannosides | 1 | 1989 | 1 | 0.020 |
Why?
| Cytochalasins | 1 | 1989 | 3 | 0.020 |
Why?
| Rosette Formation | 1 | 1989 | 17 | 0.020 |
Why?
| Gene Expression Profiling | 1 | 2016 | 1625 | 0.020 |
Why?
| Colchicine | 1 | 1989 | 27 | 0.020 |
Why?
| Sensitivity and Specificity | 1 | 2013 | 1855 | 0.020 |
Why?
| Monocytes | 2 | 1989 | 523 | 0.020 |
Why?
| Animals, Newborn | 1 | 2011 | 825 | 0.020 |
Why?
| Blood Glucose | 1 | 1997 | 1957 | 0.020 |
Why?
| DNA Replication | 1 | 1989 | 214 | 0.020 |
Why?
| Oligoclonal Bands | 1 | 2007 | 20 | 0.020 |
Why?
| Bile Ducts, Extrahepatic | 1 | 2007 | 28 | 0.020 |
Why?
| Lipid Peroxides | 1 | 1987 | 8 | 0.020 |
Why?
| Interleukin-6 | 1 | 1991 | 702 | 0.020 |
Why?
| Evaluation Studies as Topic | 1 | 1987 | 190 | 0.020 |
Why?
| Predictive Value of Tests | 1 | 2012 | 1947 | 0.020 |
Why?
| Cytotoxicity Tests, Immunologic | 1 | 2006 | 49 | 0.020 |
Why?
| Chemokine CCL8 | 1 | 2006 | 3 | 0.020 |
Why?
| Monocyte Chemoattractant Proteins | 1 | 2006 | 8 | 0.020 |
Why?
| Phospholipases A2 | 1 | 2006 | 77 | 0.020 |
Why?
| Reproducibility of Results | 1 | 2013 | 2977 | 0.020 |
Why?
| Chemokine CCL2 | 1 | 2006 | 126 | 0.020 |
Why?
| Cytosol | 1 | 2006 | 229 | 0.020 |
Why?
| DNA, Complementary | 1 | 2005 | 270 | 0.020 |
Why?
| NADPH Dehydrogenase | 1 | 2005 | 8 | 0.020 |
Why?
| Age Factors | 1 | 2013 | 3114 | 0.020 |
Why?
| Infant | 3 | 2007 | 8523 | 0.020 |
Why?
| NADH Dehydrogenase | 1 | 2005 | 18 | 0.020 |
Why?
| Immunity, Cellular | 1 | 1987 | 276 | 0.020 |
Why?
| Chemokine CXCL1 | 1 | 2004 | 69 | 0.020 |
Why?
| Oxidation-Reduction | 1 | 1988 | 931 | 0.020 |
Why?
| Translocation, Genetic | 1 | 2005 | 92 | 0.020 |
Why?
| Monitoring, Physiologic | 1 | 1987 | 288 | 0.020 |
Why?
| NADPH Oxidases | 1 | 2005 | 141 | 0.020 |
Why?
| Mice, Inbred AKR | 1 | 1983 | 35 | 0.020 |
Why?
| Leukemia, Lymphoid | 1 | 1983 | 27 | 0.020 |
Why?
| Blood Transfusion | 1 | 1987 | 312 | 0.020 |
Why?
| Leukemia, Experimental | 1 | 1983 | 28 | 0.010 |
Why?
| Lymphokines | 1 | 1983 | 132 | 0.010 |
Why?
| Acute Disease | 1 | 2006 | 984 | 0.010 |
Why?
| Necrosis | 1 | 1984 | 238 | 0.010 |
Why?
| Kinetics | 1 | 1986 | 1658 | 0.010 |
Why?
| Enzyme Activation | 1 | 2004 | 864 | 0.010 |
Why?
| Rats | 3 | 2004 | 5426 | 0.010 |
Why?
| Diagnosis, Differential | 1 | 2006 | 1423 | 0.010 |
Why?
| Cohort Studies | 1 | 2012 | 5294 | 0.010 |
Why?
| Anti-Bacterial Agents | 1 | 1991 | 1562 | 0.010 |
Why?
| Leukocyte Count | 1 | 2002 | 309 | 0.010 |
Why?
| HLA-DQ alpha-Chains | 1 | 2000 | 17 | 0.010 |
Why?
| Hematologic Neoplasms | 1 | 2002 | 135 | 0.010 |
Why?
| Genes, T-Cell Receptor alpha | 1 | 1999 | 11 | 0.010 |
Why?
| Gene Rearrangement, alpha-Chain T-Cell Antigen Receptor | 1 | 1999 | 21 | 0.010 |
Why?
| United States | 1 | 2016 | 13272 | 0.010 |
Why?
| Cell Culture Techniques | 1 | 2002 | 354 | 0.010 |
Why?
| Prospective Studies | 3 | 1996 | 6704 | 0.010 |
Why?
| Pregnancy | 1 | 2011 | 5854 | 0.010 |
Why?
| Rats, Sprague-Dawley | 1 | 2004 | 2501 | 0.010 |
Why?
| Clone Cells | 1 | 1999 | 255 | 0.010 |
Why?
| Feasibility Studies | 1 | 2002 | 780 | 0.010 |
Why?
| Azathioprine | 1 | 1998 | 55 | 0.010 |
Why?
| Incidence | 2 | 1995 | 2527 | 0.010 |
Why?
| Prednisone | 1 | 1998 | 234 | 0.010 |
Why?
| Infusions, Intra-Arterial | 1 | 1996 | 46 | 0.010 |
Why?
| Metabolic Clearance Rate | 1 | 1996 | 111 | 0.010 |
Why?
| Risk Assessment | 1 | 2006 | 3213 | 0.010 |
Why?
| Injections, Intravenous | 1 | 1996 | 217 | 0.010 |
Why?
| Risk | 1 | 1999 | 890 | 0.010 |
Why?
| Transplantation, Autologous | 1 | 1996 | 189 | 0.010 |
Why?
| Dogs | 1 | 1996 | 382 | 0.010 |
Why?
| Blood Group Incompatibility | 1 | 1995 | 15 | 0.010 |
Why?
| ABO Blood-Group System | 1 | 1995 | 36 | 0.010 |
Why?
| Cytomegalovirus | 1 | 1995 | 144 | 0.010 |
Why?
| Diabetic Nephropathies | 1 | 1998 | 292 | 0.010 |
Why?
| Species Specificity | 2 | 1988 | 578 | 0.010 |
Why?
| Cadaver | 1 | 1995 | 325 | 0.010 |
Why?
| Drug Costs | 1 | 1994 | 100 | 0.010 |
Why?
| Infusions, Intravenous | 1 | 1994 | 396 | 0.010 |
Why?
| Antibodies, Viral | 1 | 1995 | 551 | 0.010 |
Why?
| Breast Neoplasms | 1 | 2002 | 1994 | 0.010 |
Why?
| Length of Stay | 1 | 1994 | 1077 | 0.010 |
Why?
| Rats, Inbred SHR | 1 | 1988 | 41 | 0.010 |
Why?
| Deferoxamine | 1 | 1988 | 18 | 0.010 |
Why?
| Malondialdehyde | 1 | 1988 | 31 | 0.010 |
Why?
| Biotransformation | 1 | 1988 | 52 | 0.010 |
Why?
| Injections, Subcutaneous | 1 | 1988 | 137 | 0.000 |
Why?
| Tissue Distribution | 1 | 1988 | 339 | 0.000 |
Why?
| Kidney Cortex | 1 | 1986 | 31 | 0.000 |
Why?
| Kidney Medulla | 1 | 1986 | 32 | 0.000 |
Why?
| Administration, Oral | 1 | 1988 | 786 | 0.000 |
Why?
| Suppressor Factors, Immunologic | 1 | 1983 | 4 | 0.000 |
Why?
| Blood Physiological Phenomena | 1 | 1983 | 15 | 0.000 |
Why?
| Mice, Inbred CBA | 1 | 1983 | 62 | 0.000 |
Why?
| Thymidine | 1 | 1983 | 64 | 0.000 |
Why?
| Rats, Inbred Strains | 1 | 1983 | 392 | 0.000 |
Why?
| Kidney Diseases | 1 | 1988 | 446 | 0.000 |
Why?
|
|
Freed's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|